NCT05616013: Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese |
|
|
| Active, not recruiting | 2 | 507 | US, RoW | Bimagrumab, Semaglutide, Wegovy, Ozempic, Bimagrumab Placebo | Eli Lilly and Company, Versanis Bio, Inc. | Obesity, Obese, Overweight or Obesity | 05/24 | 06/25 | | |